Effect of a XXXX and  @entity5224 ophthalmic solution on ocular comfort and tear-film instability after @entity231 surgery.

@entity1 @entity2194 @entity231 @entity5224 @entity937 @entity936 @entity479 @entity941 @entity4023
PURPOSE: To evaluate the efficacy and safety of using @entity4023 0.1% and @entity5224 0.5% artificial tears for @entity2194 and tear-film stability in eyes after @entity231 surgery. SETTING: Twenty ophthalmic centers in Italy. DESIGN: Prospective randomized case series. METHODS: This study enrolled @entity1 scheduled for unilateral @entity231 surgery. After surgery, @entity1 received artificial tears and a topical steroid-antibiotic (study group) or topical @entity479 -antibiotic alone (control group) and were assessed postoperatively at 1 and 5 weeks. Outcome measures were @entity937 ( @entity937 ), ocular surface disease index (OSDI), frequency of @entity936 evaluated using a visual analog scale (VAS), and corneal @entity941 staining. RESULTS: The study comprised 282 @entity1 . At 5 weeks, the mean @entity937 was statistically significantly higher in the study group than in the control group (P = .0003). The mean OSDI score statistically significantly improved in both groups from 1 to 5 weeks (P < .0001 for both groups); however, there was no statistically significant difference between the groups at these timepoints. The artificial tears statistically significantly improved VAS-assessed @entity936 in the study group compared with the control group at 5 weeks (P < .001). The mean corneal @entity941 staining was significantly reduced in the study group compared with the control group at 5 weeks (P = .002 versus P = .05, respectively). No treatment-related adverse events were reported. CONCLUSION: @entity4023 0.1% and @entity5224 0.5% ophthalmic solution was effective and well tolerated in reducing @entity2194 and improving the clinical outcome after @entity231 surgery. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned.
